Tumour necrosis factor antagonists and early postoperative complications in patients with inflammatory joint disease undergoing elective orthopaedic surgery
| Autor: | P Johnson, D M Grennan, M J Hayton, J Gray, S C Talwalkar |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male Drug medicine.medical_specialty Necrosis media_common.quotation_subject Immunology Arthritis Disease General Biochemistry Genetics and Molecular Biology Arthritis Rheumatoid Postoperative Complications Rheumatology medicine Humans Immunologic Factors Immunology and Allergy Letters Aged Retrospective Studies media_common Tumor Necrosis Factor-alpha business.industry Retrospective cohort study Middle Aged medicine.disease Surgery Antirheumatic Agents Rheumatoid arthritis Female Tumor necrosis factor alpha medicine.symptom business |
| Zdroj: | Annals of the Rheumatic Diseases. 64:650-651 |
| ISSN: | 0003-4967 |
| DOI: | 10.1136/ard.2004.028365 |
| Popis: | Tumour necrosis factor α (TNFα) antagonists are now established as therapeutic agents for active rheumatoid arthritis (RA) resistant to conventional drug treatment.1 However, they decrease resistance to infection, including unusual infections such as tuberculosis,2,3 and in an experimental setting have been shown to impair wound healing.4 Previous studies have shown that TNFα antagonists do not increase the risk of postoperative surgical complications in patients with Crohn’s disease who undergo resective bowel surgery,5,6 but the safety of these drugs in patients with RA who undergo elective orthopaedic surgery has not yet been established. As over 10% of patients with RA at our institution receiving antirheumatic drugs still require some form of … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|